Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied genotype-phenotype relationships in iPSCs using data from approximately one thousand donors.

The incidence of colorectal cancers in young adults is increasing. At the same time, the proportion of overweight and obese young people is also on the rise. Whether there is a connection between these two observations, however, was not known until now. Scientists at the DKFZ have now shown that the risk of early colorectal cancer is significantly increased in overweight young people compared to normal-weight peers.

After infections or blood loss, the body must compensate for the loss of blood cells as quickly as possible. This has long been considered the task of the hematopoietic stem cells in the bone marrow. But scientists at the German Cancer Research Center (DKFZ) have now discovered in mice that a certain population of progenitor cells takes over this task: This accelerates the regeneration of the blood cells.

A high-fat, high-sugar diet damages the liver in the long term. Scientists at the German Cancer Research Center (DKFZ) have now identified a characteristic change in the molecular signaling pathways of liver cells in mice that were exposed to such a diet for weeks. It fuels the division activity of hepatocytes and correlates with the risk of patients suffering liver failure after liver surgery.

The Bayer Foundation's Early Excellence in Science Award 2024 in the category of Data Science goes to Ivana Winkler of the German Cancer Research Center (DKFZ). Winkler's work uncovered the unexpected effect of female reproductive capacity: the constantly recurring remodeling of the organs of the female reproductive tract during the sexual cycle leads to fibrosis and chronic inflammation over the years.

This year, the Brain Prize worth more than one million euros, honors pioneering work on nervous system-cancer interactions: Neurologist Frank Winkler, who researches at the Heidelberg University and at the German Cancer Research Center and treats patients with brain tumors at the Heidelberg University Hospital, discovered that nerve cells in the brain communicate with brain tumor cells. This causes the disease to progress.

Heidelberg University scientists are to receive three ERC Synergy Grants – three highly endowed grants of the European Research Council – for pioneering research projects by several teams working in collaboration.

Researchers at the Medical Faculty of Heidelberg University and the Heidelberg University Hospital have used modified rabies viruses to label glioblastoma tumour cells and their direct cell contacts in the mouse brain. The new method showed that the tumour cells are connected to different types of nerve cells throughout the entire brain at a very early stage of the disease.

Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have developed antibodies that have two antigen-binding sites and can couple cancer cells with effector cells of the immune system. In laboratory tests, these bridging antibodies, together with an enhancer antibody, were able to specifically mobilize the body's own immune defenses and destroy breast cancer cells.

Why do metastases often only appear after the original tumor has been surgically removed? Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim Medical Faculty of Heidelberg University have now published an explanation for this phenomenon. They were able to identify a messenger substance of the cancer cells that locally promotes the growth of the primary tumor.

How can camera images be used during minimally invasive surgeries to assess whether the operated organ is sufficiently perfused with blood? Scientists from the German Cancer Research Center (DKFZ) and the Städtisches Klinikum Karlsruhe have now succeeded in automatic monitoring of ischemia during a kidney surgery using only the optical properties of the tissue and not relying on injection of contrast agent.

Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance mechanism was successfully overcome using a second drug.

Article - 20/01/2020

Brain tumour patients could benefit from heavy ion therapy

Glioblastoma is a malignant brain tumour. It does not respond anywhere near as well to conventional forms of therapy than other tumours because it contains particularly resistant cancer cells. Scientists at the Heidelberg Ion Beam Therapy Center (HIT) at Heidelberg University Hospital and the German Cancer Research Center have shown that heavy ion therapy is effective against these cells.

Genetic alterations that promote the development and spread of tumors are difficult to identify. This is especially true for mutations in the non-protein-coding regions of the genome, which include all important regulatory sequences. Scientists at the German Cancer Research Center have now published an algorithm that detects cancer drivers in both the protein-coding and non-coding regions of the genome.

Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status.

Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.

Women have an increased risk of breast cancer if they have a family history of this disease. However, the risk may also be higher if first-degree family members have another type of cancer, according to a study by a team of scientists and physicians from the National Center for Tumor Diseases (NCT) Heidelberg, the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD), as well as international colleagues.

Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

Through a complex, self-reinforcing feedback mechanism, colorectal cancer cells make room for their own expansion by driving surrounding healthy intestinal cells to death - while simultaneously fueling their own growth. This feedback loop is driven by an activator of the innate immune system. Researchers from the German Cancer Research Center (DKFZ) and the University of Heidelberg discovered this mechanism in the intestinal tissue of fruit…

Tumour organoids facilitate drug discovery - 20/07/2023

Drug screening for children with cancer using patient-specific miniature tumours

Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.

In the medicine of the future, tiny robots will navigate independently through tissue and medical instruments will indicate their position inside the body during surgery. Both require doctors to be able to localize and control the devices precisely and in real time. Scientists from the German Cancer Research Center (DKFZ) have now described a signaling method based on an oscillating magnet that can significantly improve such medical applications.

Gender-specific differences - 18/06/2024

Gender medicine: Why is good healthcare not a matter of course for everyone?

Gender medicine is the study of gender-specific health differences. Many diseases manifest themselves differently in men and women and therapies do not always have the same effect depending on the sex of the patient being treated. There is currently not enough data on these differences. Research teams including the one led by Professor Dr. Dr. Sonja Loges from the University Medical Centre Mannheim and the DKFZ are seeking to change this.

Chromosomal instability plays a role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia.

A key enzyme in sugar metabolism is inactivated particularly easily and efficiently by oxidative stress. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now shown that with this oxidation, cells switch to an alternative sugar breakdown pathway and can thus escape oxidative stress. Cancer cells in particular benefit from this mechanism, which can also protect them from therapy-related damage.